Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
293
datasets available to search
ShareScore release 0.9.0
Dataset results
293 results for “PARP”
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
ClinicalTrials.gov study NCT05759546. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)
ClinicalTrials.gov study NCT04174716. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
ClinicalTrials.gov study NCT04041128. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
ClinicalTrials.gov study NCT04675320. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
ClinicalTrials.gov study NCT06612814. IPD Sharing: NO. Countries: 1. Publications: 0.
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation i
ClinicalTrials.gov study NCT05378204. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP
ClinicalTrials.gov study NCT04826198. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
ClinicalTrials.gov study NCT04582552. IPD Sharing: NO. Countries: 1. Publications: 0.
Expression of PARP-1 in Multiple Sclerosis Patients
ClinicalTrials.gov study NCT05196425. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
ClinicalTrials.gov study NCT04774406. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
ClinicalTrials.gov study NCT02571725. IPD Sharing: NO. Countries: 1. Publications: 0.
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA M
ClinicalTrials.gov study NCT05807126. IPD Sharing: YES. Countries: 1. Publications: 0.
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
ClinicalTrials.gov study NCT06541171. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
ClinicalTrials.gov study NCT04276376. IPD Sharing: NO. Countries: 1. Publications: 0.
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.
ClinicalTrials.gov study NCT04573933. IPD Sharing: YES. Countries: 1. Publications: 0.
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
ClinicalTrials.gov study NCT04194554. IPD Sharing: YES. Countries: 1. Publications: 0.
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ClinicalTrials.gov study NCT03334500. IPD Sharing: NO. Countries: 1. Publications: 0.
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
ClinicalTrials.gov study NCT05636540. IPD Sharing: NO. Countries: 1. Publications: 0.
PD1 and PARP for Maintenance Therapy in NSLLC
ClinicalTrials.gov study NCT05392686. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
ClinicalTrials.gov study NCT07000344. IPD Sharing: NO. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.